Provided by Tiger Trade Technology Pte. Ltd.

SKB BIO

455.000
-5.600-1.22%
Volume:1K
Turnover:637.00K
Market Cap:108.75B
PE:-234.96
High:455.000
Open:455.000
Low:455.000
Close:460.600
52wk High:581.000
52wk Low:339.600
Shares:239.00M
HK Float Shares:177.00M
Volume Ratio:- -
T/O Rate:0.00%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.937
ROE:2.92%
ROA:0.03%
PB:17.43
PE(LYR):-234.96
PS:44.61

Loading ...

Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) Is Down 14.8% After ASCO NSCLC Data Spotlight - Has The Bull Case Changed?

Simply Wall St.
·
Jun 06

Shares of SKB BIO Surge Over 7% on Milestone Breakthrough in OptiTROP-Lung05 Study

Stock News
·
Jun 05

Movement Alert|Kelun-Biotech Rises 3.54% in Regular Trading, Buyback Plan and ASCO Clinical Data Provide Dual Catalysts

Market Focus
·
Jun 05

Movement Alert|Kelun-Biotech Rises 3.08% at Open, Proposed Buyback of Up to 10% H Shares Boosts Sentiment

Market Focus
·
Jun 05

SKB BIO Announces Investment in Structured Deposit Product

Stock News
·
Jun 03

Sichuan Kelun-Biotech Biopharmaceutical Co - Subscribes for Czb Structured Deposit Iii of RMB190 Mln on April 22, 2026

THOMSON REUTERS
·
Jun 03

Movement Alert|Kelun-Biotech Biopharmaceutical Falls 3.17% in Regular Trading, Performance Slowdown and Chairman Stake Reduction Continue to Pressure Shares

Market Focus
·
Jun 03

Kelun-Biotech says SKB500 posts 42.7% response rate in first-in-human solid tumor study at ASCO 2026

Reuters
·
Jun 03

Movement Alert|Kelun-Biotech Biopharmaceutical Falls 6.11% in Regular Trading, Chairman Consecutive Share Sales Compound Performance Concerns

Market Focus
·
Jun 02

Movement Alert|Kelun-Biotech Biopharmaceutical Rises 4.5% in Regular Trading, Named Among June Top Golden Stocks with ASCO Data Catalyzing

Market Focus
·
Jun 01

Stock Track | SKB BIO Soars 5.67% at Market Open on Positive Drug Pipeline Developments and Inclusion in Top Stock Picks

Stock Track
·
Jun 01

June Investment Strategy and Top Ten Stock Picks for Hong Kong Stocks

Stock News
·
Jun 01

Kelun-Biotech says Phase III study shows sac-TMT plus Keytruda extends PFS in first-line PD-L1+ NSCLC

Reuters
·
May 30

Kelun-Biotech says China regulator accepts NDA for lunbotinib in RET fusion-positive NSCLC

Reuters
·
May 30

Stock Track | SKB BIO Plummets 5.02% Intraday as Profit-Taking Hits Following Widening Losses Despite Prior Clinical Data Rally

Stock Track
·
May 28

Movement Alert|Kelun-Biotech Biopharmaceutical Falls 3.21% in Regular Trading, Profit-Taking Triggered by Widening Net Losses Despite Prior Rally on Clinical Data

Market Focus
·
May 28

Movement Alert|Kelun-Biotech Biopharmaceutical Rises 3.07% in Regular Trading, Nomura Raises Target Price to HK$544.42 on Encouraging Phase III ADC Data

Market Focus
·
May 27

Movement Alert|Kelun-Biotech Biopharmaceutical Rises 3.12% in Regular Trading, ASCO Annual Meeting Data Continues to Catalyze Pipeline Value Reassessment

Market Focus
·
May 26

Kelun Biotech to Present Study Results of Cancer Drugs at American Oncology Meeting

MT Newswires Live
·
May 22

SKB BIO Receives "Buy" Rating from China Post Securities on Anticipated Global Pipeline Value Realization

Stock News
·
May 22